coumarin has been researched along with Acute Liver Injury, Drug-Induced in 22 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "No evidence was obtained that the studied polymorphism in CYP2A6 is a determinant of the coumarin-associated liver dysfunction." | 9.10 | Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. ( Burian, M; Freudenstein, J; Henneicke-von Zepelin, HH; Legrum, W; Naser-Hijazi, B; Tegtmeier, M, 2003) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 6.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| "No evidence was obtained that the studied polymorphism in CYP2A6 is a determinant of the coumarin-associated liver dysfunction." | 5.10 | Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. ( Burian, M; Freudenstein, J; Henneicke-von Zepelin, HH; Legrum, W; Naser-Hijazi, B; Tegtmeier, M, 2003) |
| "Lympidem is a coumarin derivative which is advocated for treatment of mainly chronic lymphedema by the manufacturer." | 3.75 | Lympidem (a coumarin derivative) induced reversible hepatotoxicity in an adult Sri Lankan. ( Jayawardana, MA; Satarasinghe, RL, 2009) |
| "The administration of single doses of coumarin to the rat was found to produce hepatic centrilobular necrosis and also to depress a number of hepatic enzyme activities within 24 h." | 3.67 | Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. ( Lake, BG, 1984) |
| "Coumarin is a secondary phytochemical with hepatotoxic and carcinogenic properties." | 2.46 | Toxicology and risk assessment of coumarin: focus on human data. ( Abraham, K; Heinemeyer, G; Lampen, A; Lindtner, O; Wöhrlin, F, 2010) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 2.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| "Coumarin is a drug which is extensively used to treat lymphedema." | 2.40 | [Acute cytolytic hepatitis caused by coumarin. 2 cases]. ( Becker, MC; Beurton, I; Bresson-Hadni, S; Carbillet, JP; Hrusovsky, S; Koch, S; Miguet, JP; Monnot, B; Vanlemmens, C, 1997) |
| " Coumarin is less toxic in the baboon, gerbil and certain strains of mice, which resemble man in their extensive formation of the 7-hydroxy metabolite." | 2.38 | Species differences in the metabolism and hepatotoxicity of coumarin. ( Fentem, JH; Fry, JR, 1993) |
| "Coumarin was administered to male rats as a single dose or for 4 consecutive days, and samples were obtained 4 or 24 h after a single dose or 24 h after the repeated doses." | 1.43 | Relationship between coumarin-induced hepatocellular toxicity and mitochondrial function in rats. ( Fujii, W; Hori, H; Kitagawa, Y; Ozaki, K; Tanaka, Y, 2016) |
| " A single toxic dose of CCl(4) (1." | 1.37 | Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats. ( Atmaca, M; Deniz Obay, B; Ketani, A; Murat Bilgin, H; Ozekinci, S; Taşdemir, E, 2011) |
| "Treatment with coumarin reduced hepatic microsomal ethylmorphine N-demethylase and 7-ethoxycoumarin O-deethylase activities, whereas one or both mixed-function oxidases appeared to be induced by treatment with 3,4-DMC, 4-MC, 3-MOHC and 4-MOHC." | 1.29 | Studies on the acute effects of coumarin and some coumarin derivatives in the rat. ( Evans, JG; Lake, BG; Lewis, DF; Price, RJ, 1994) |
| "Coumarin (200 mg/kg) was hepatotoxic to both strains, resulting in 2- to 15-fold plasma aminotransferase elevations, mild subcapsular linear hepatocyte necrosis after 24 hr, and, in some C3H/He mice, centrilobular necrosis." | 1.29 | Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents. ( Cottrell, S; Lake, BG; Oliver, K; Powell, CJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Hassan, AA | 1 |
| Abu Hafsa, SH | 1 |
| Elghandour, MMMY | 1 |
| Kanth Reddy, PR | 1 |
| Monroy, JC | 1 |
| Salem, AZM | 1 |
| Teng, S | 1 |
| Barcellini-Couget, S | 1 |
| Beaudouin, R | 1 |
| Brochot, C | 1 |
| Desousa, G | 1 |
| Rahmani, R | 1 |
| Pery, AR | 1 |
| Tanaka, Y | 1 |
| Fujii, W | 1 |
| Hori, H | 1 |
| Kitagawa, Y | 1 |
| Ozaki, K | 1 |
| Satarasinghe, RL | 1 |
| Jayawardana, MA | 1 |
| Abraham, K | 1 |
| Wöhrlin, F | 1 |
| Lindtner, O | 1 |
| Heinemeyer, G | 1 |
| Lampen, A | 1 |
| Murat Bilgin, H | 1 |
| Atmaca, M | 1 |
| Deniz Obay, B | 1 |
| Ozekinci, S | 1 |
| Taşdemir, E | 1 |
| Ketani, A | 1 |
| Oh, H | 1 |
| Ko, EK | 1 |
| Jun, JY | 1 |
| Oh, MH | 1 |
| Park, SU | 1 |
| Kang, KH | 1 |
| Lee, HS | 1 |
| Kim, YC | 1 |
| Burian, M | 1 |
| Freudenstein, J | 1 |
| Tegtmeier, M | 2 |
| Naser-Hijazi, B | 1 |
| Henneicke-von Zepelin, HH | 1 |
| Legrum, W | 1 |
| Adam, BS | 1 |
| Pentz, R | 1 |
| Siegers, CP | 1 |
| Strubelt, O | 1 |
| Farinola, N | 1 |
| Piller, NB | 1 |
| Uehara, T | 1 |
| Kiyosawa, N | 1 |
| Shimizu, T | 1 |
| Omura, K | 1 |
| Hirode, M | 1 |
| Imazawa, T | 1 |
| Mizukawa, Y | 1 |
| Ono, A | 1 |
| Miyagishima, T | 1 |
| Nagao, T | 1 |
| Urushidani, T | 1 |
| Colebunders, R | 1 |
| Schutyser, G | 1 |
| De Schepper, A | 1 |
| Verselder, R | 1 |
| Lake, BG | 3 |
| Casley-Smith, JR | 2 |
| Fentem, JH | 1 |
| Fry, JR | 1 |
| Evans, JG | 1 |
| Lewis, DF | 1 |
| Price, RJ | 1 |
| Cottrell, S | 1 |
| Oliver, K | 1 |
| Powell, CJ | 1 |
| Ghosh, P | 1 |
| Markin, RS | 1 |
| Sorrell, MF | 1 |
| Koch, S | 1 |
| Beurton, I | 1 |
| Bresson-Hadni, S | 1 |
| Monnot, B | 1 |
| Hrusovsky, S | 1 |
| Becker, MC | 1 |
| Vanlemmens, C | 1 |
| Carbillet, JP | 1 |
| Miguet, JP | 1 |
| Loprinzi, CL | 1 |
| Sloan, J | 1 |
| Kugler, J | 1 |
5 reviews available for coumarin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Toxicology and risk assessment of coumarin: focus on human data.
Topics: Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Coumarins; Edema; Flavoring Agen | 2010 |
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?
Topics: Animals; Chemical and Drug Induced Liver Injury; Coumarins; Humans; Liver Diseases; Lymphedema; Phar | 2007 |
Species differences in the metabolism and hepatotoxicity of coumarin.
Topics: Animals; Chemical and Drug Induced Liver Injury; Coumarins; Humans; In Vitro Techniques; Liver Disea | 1993 |
Coumarin-induced hepatic necrosis.
Topics: Aged; Antineoplastic Agents; Biopsy; Chemical and Drug Induced Liver Injury; Coumarins; Humans; Live | 1997 |
[Acute cytolytic hepatitis caused by coumarin. 2 cases].
Topics: Acute Disease; Adult; Anticoagulants; Chemical and Drug Induced Liver Injury; Coumarins; Female; Hum | 1997 |
1 trial available for coumarin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.
Topics: Adult; Aged; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; | 2003 |
16 other studies available for coumarin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Dietary Supplementation with sodium bentonite and coumarin alleviates the toxicity of aflatoxin B
Topics: Aflatoxin B1; Animal Feed; Animals; Bentonite; Cecum; Chemical and Drug Induced Liver Injury; Coumar | 2019 |
BK/TD models for analyzing in vitro impedance data on cytotoxicity.
Topics: Animal Testing Alternatives; Animals; Benzophenones; Cell Survival; Chemical and Drug Induced Liver | 2015 |
Relationship between coumarin-induced hepatocellular toxicity and mitochondrial function in rats.
Topics: Aconitate Hydratase; Animals; Chemical and Drug Induced Liver Injury; Coumarins; Dose-Response Relat | 2016 |
Lympidem (a coumarin derivative) induced reversible hepatotoxicity in an adult Sri Lankan.
Topics: Chemical and Drug Induced Liver Injury; Coumarins; Female; Humans; Lower Extremity; Lymphedema; Midd | 2009 |
Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats.
Topics: Animals; Antioxidants; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Couma | 2011 |
Hepatoprotective and free radical scavenging activities of prenylflavonoids, coumarin, and stilbene from Morus alba.
Topics: Biphenyl Compounds; Cell Line; Chemical and Drug Induced Liver Injury; Coumarins; Flavonoids; Free R | 2002 |
Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarin.
Topics: Alanine Transaminase; Animals; Anticoagulants; Bile; Chemical and Drug Induced Liver Injury; Coumari | 2005 |
Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Chemical and Drug Indu | 2008 |
Hepatic haematoma, a complication during anticoagulant therapy. A case report.
Topics: Chemical and Drug Induced Liver Injury; Coumarins; Female; Hematoma; Humans; Liver; Liver Diseases; | 1984 |
Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat.
Topics: Acetylcysteine; Animals; Chemical and Drug Induced Liver Injury; Coumarins; Kinetics; Liver; Liver D | 1984 |
Frequency of coumarin hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Coumarins; Dose-Response Relationship, Drug; Humans; Inciden | 1995 |
Studies on the acute effects of coumarin and some coumarin derivatives in the rat.
Topics: 7-Alkoxycoumarin O-Dealkylase; Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical | 1994 |
Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents.
Topics: Alanine Transaminase; Animals; Aroclors; Aspartate Aminotransferases; beta-Naphthoflavone; Chemical | 1996 |
Coumarin-induced hepatotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Coumarins; Female; | 1997 |